Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2007 2
2008 3
2009 1
2010 3
2011 2
2013 1
2014 1
2015 2
2017 1
2018 3
2020 2
2021 2
2022 3
2023 2
2024 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells.
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D, Adams A, Bianchi L, Turner B, Marta M, Schmierer K, Baker D, Giovannoni G, Gnanapavan S. Ammoscato F, et al. Among authors: bianchi l. Clin Immunol. 2024 Dec;269:110380. doi: 10.1016/j.clim.2024.110380. Epub 2024 Oct 18. Clin Immunol. 2024. PMID: 39428028 Free article.
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
Dobson R, Holden D, Vickaryous N, Bestwick J, George K, Sayali T, Bianchi L, Wafa M, Gold J, Giovannoni G. Dobson R, et al. Among authors: bianchi l. Mult Scler. 2024 Jan;30(1):63-70. doi: 10.1177/13524585231215268. Epub 2023 Dec 22. Mult Scler. 2024. PMID: 38131621 Free PMC article. Clinical Trial.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S, Holden DW, Marta M, Mathews J, Turner BP, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: bianchi l. Ther Adv Neurol Disord. 2023 Nov 10;16:17562864231200627. doi: 10.1177/17562864231200627. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37954917 Free PMC article.
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X, Yildiz O, Adams A, Bianchi L, Blain C, Chapman C, Chung K, Constantinescu CS, Dalton C, Farrell RA, Fisniku L, Ford H, Gran B, Hobart J, Khaleeli Z, Mattoscio M, Pavitt S, Pearson O, Peruzzotti-Jametti L, Scalfari A, Sharrack B, Silber E, Tallantyre EC, Webb S, Turner BP, Marta M, Gnanapavan S, Juliusson G, Giovannoni G, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: bianchi l. Ther Adv Neurol Disord. 2021 Nov 25;14:17562864211057661. doi: 10.1177/17562864211057661. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 35173808 Free PMC article.
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B, Marta M, Schmierer K, Giovannoni G, Gnanapavan S. Reyes S, et al. Among authors: bianchi l. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 21;7(6):e880. doi: 10.1212/NXI.0000000000000880. Print 2020 Nov. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32826298 Free PMC article.
Serum neurofilament-light concentration and real-world outcome in MS.
Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Wynford-Thomas RA, Joseph F, Giovannoni G, Gnanapavan S, Robertson NP, Marta M, Tallantyre EC. Anderson V, et al. Among authors: bianchi l. J Neurol Sci. 2020 Oct 15;417:117079. doi: 10.1016/j.jns.2020.117079. Epub 2020 Aug 3. J Neurol Sci. 2020. PMID: 32781395
31 results